GUANGZHOU INNOGEN PHARMACE-H signed an agreement valued at over $1.0B with Arcera Life Sciences on Thursday morning to commercialize its GLP-1 receptor agonist drugs. The licensing deal expands the China-based developer's reach for its type 2 diabetes treatments into emerging international markets. The partnership provides the Abu Dhabi-headquartered firm exclusive rights to commercialize Efsubaglutide Alfa across selected territories.

Global Expansion Strategy